Universal OMICS

Universal OMICS is developing DRUP_Drug Predictor, an artificial intelligence platform that enables pharmaceutical, biotechnology, and nutraceutical companies to predict drug efficacy and safety at early stages, reducing development time and R&D costs by up to 80%. • Predicts efficacy and toxicity of any type of molecule at early stages • Enables Go/No-Go decisions in days instead of months • Simultaneously analyzes multiple metabolic targets • Can reduce R&D time and costs by up to 80% • Currently integrating quantum computing capabilities to enhance molecular efficacy prediction and formulation analysis DRUP supports molecular screening, formulation design, and reformulation through a structured end-to-end workflow. It uses machine-learning models trained on curated universal databases to predict disease-specific efficacy for molecules of any type and size. Its first application focuses on arrhythmia (cardiac disease), integrating multiple molecular descriptors together with up to 15 metabolic targets involved in cardiac physiology. DRUP generates comprehensive, decision-ready reports including efficacy prediction, ADME (Absorption, Distribution, Metabolism, and Excretion), toxicity, mechanisms of action, drug interactions, and clinical and commercial insights. Universal OMICS is currently working on the application of quantum computing to DRUP in collaboration with strategic technology partners, aiming to enable molecular and formulation efficacy calculations with intermolecular and intracellular precision.